ArticleNeurobiology of aging2017
Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease.
Article in Neurobiology of aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Genome-wide association study of 23,500 individuals identifies 7 loci associated with brain ventricular volume.Nature communications · 2018Pooled it
- Evans' Index and Frontal and Occipital Horn Ratio in Correlation to Volumetric Data of Lateral Ventricles in a Population-based MRI Study.Clinical neuroradiology · 2026Article
- Comparison of Three Automated Measurements of Ventricular Volumes of the Brain.Journal of imaging informatics in medicine · 2026Article
- Longitudinal brain morphometry in Parkinson's disease clinical subtypes: Distinct signatures forecast behavioral change within subtypes.Parkinsonism & related disorders · 2026Article
- Entorhinal cortex atrophy mediates the association of plasma p-tau181, GFAP, and NfL with cognitive impairment in Parkinson's disease.Frontiers in aging neuroscience · 2026Article
- Letter to the editor: clinical utility of visual rating scales in detecting mild cognitive impairment in Parkinson's disease: a focus on medial temporal and occipital atrophy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Predictor model for mild cognitive impairment in Parkinson's disease using visual rating scales.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Synthetic MRI study of brain volume and subcortical myelin in various Parkinson's disease motor subtypes.NPJ Parkinson's disease · 2025Article
- Enhanced Detection of Age-Related and Cognitive Declines Using Automated Hippocampal-To-Ventricle Ratio in Alzheimer's Patients.Human brain mapping · 2025Article
- The disease-specific structural pattern in Parkinson's disease and its cortical characteristics associated with gene function: a 7-Tesla MRI study.Journal of neurology · 2025Article
- Kidins220-deficient hydrocephalus mice exhibit altered glial phenotypes and AQP4 differential regulation in the retina and optic nerve, with preserved retinal ganglion cell survival.Fluids and barriers of the CNS · 2025Article
- Deep learning-based automatic segmentation of brain structures on MRI: A test-retest reproducibility analysis.Computational and structural biotechnology journal · 2025Article
- Accumulation of Cerebrospinal Fluid, Ventricular Enlargement, and Cerebral Folate Metabolic Errors Unify a Diverse Group of Neuropsychiatric Conditions Affecting Adult Neocortical Functions.International journal of molecular sciences · 2024Article
- Intravenous arachnoid granulation hypertrophy in patients with Parkinson disease.NPJ Parkinson's disease · 2024Article
- Dynamics of Cognitive Impairment in MCI Patients over a Three-Year Period: The Informative Role of Blood Biomarkers, Neuroimaging, and Genetic Factors.Diagnostics (Basel, Switzerland) · 2024Article
- Structural neuroimaging markers of normal pressure hydrocephalus versus Alzheimer's dementia and Parkinson's disease, and hydrocephalus versus atrophy in chronic TBI-a narrative review.Frontiers in neurology · 2024Review
- Mild cognitive impairment in Parkinson's disease: current view.Frontiers in cognition · 2024Review
- How should we be using biomarkers in trials of disease modification in Parkinson's disease?Brain : a journal of neurology · 2023Article
- The Anatomic Variability of the Lateral Ventricles of the Human Brain Depending on Age and Sex.Cureus · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 5 countries.
Funding
Abstract
We investigated whole-brain atrophy and ventricular enlargement over 18 months in nondemented Parkinson's disease (PD) and examined their associations with clinical measures and baseline CSF markers. PD subjects (n = 100) were classified at baseline into those with mild cognitive impairment (MCI; PD-MCI, n = 36) and no cognitive impairment (PD-NC, n = 64). Percentage of whole-brain volume change (PBVC) and ventricular expansion over 18 months were assessed with FSL-SIENA and ventricular enlargement (VIENA) respectively. PD-MCI showed increased global atrophy (-1.1% ± 0.8%) and ventricular enlargement (6.9 % ± 5.2%) compared with both PD-NC (PBVC: -0.4 ± 0.5, p < 0.01; VIENA: 2.1% ± 4.3%, p < 0.01) and healthy controls. In a subset of 35 PD subjects, CSF levels of tau, and Aβ42/Aβ40 ratio were correlated with PBVC and ventricular enlargement respectively. The sample size required to demonstrate a 20% reduction in PBVC and VIENA was approximately 1/15th of that required to detect equivalent changes in cognitive decline. These findings suggest that longitudinal MRI measurements have potential to serve as surrogate markers to complement clinical assessments for future disease-modifying trials in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.